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Background: Survivorship care plans (SCPs) are written treatment summaries and follow-up care plans that are
intended to facilitate communication and coordination of care among survivors, cancer care providers, and primary
care providers. A growing number of guidelines for the use of SCPs exist, yet SCP use in the United States remains
limited. Limited use of SCPs may be due to poor quality of these guidelines. The purpose of the study was to evaluate
the quality of guidelines for SCP use, tools that are intended to promote evidence-based medicine.
Methods: We conducted a comprehensive search of the literature using MEDLINE/PubMed, EMBASE (Excerpta Medica
Database), and CINAHL (Cumulative Index to Nursing and Allied Health Literature) published through April 2014,
in addition to grey literature sources and bibliographic and expert reviews. Guideline quality was assessed using
the AGREE II instrument (Appraisal of Guidelines for Research and Evaluation, 2nd edition), a tool developed by
an international group of scientists to advance the quality of clinical practice guidelines. To promote consistency
with extant studies using the AGREE II instrument and to clearly and unambiguously identify potentially useful
guidelines for SCP use, we also summarized AGREE II scores by strongly recommending, recommending, or not
recommending the guidelines that we evaluated.
Results: Of 128 documents screened, we included 16 guidelines for evaluation. We did not strongly recommend
any of the 16 guidelines that we evaluated; we recommended 5 and we did not recommend 11. Overall, guidelines
scored highest on clarity of presentation (i.e., guideline language, structure, and format): Guidelines were
generally unambiguous in their recommendations that SCPs should be used. Guidelines scored lowest on
applicability (i.e., barriers and facilitators to implementation, implementation strategies, and resource implications
of applying the guideline): Few guidelines discussed facilitators and barriers to guideline application; advice and
tools for implementing guidelines were vague; and none explicitly discussed resource implications of
implementing the guidelines.
Conclusions: Guidelines often advocated survivorship care plan use without justification or suggestions for
implementation. Improved guideline quality may promote survivorship care plan use.
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The transition from cancer treatment to follow-up care
is often challenging for the nearly 15 million cancer survi-
vors in the United States [1]. To facilitate survivors’ transi-
tions, the Institute of Medicine (IOM) recommends that
cancer care providers develop and deliver to survivors and
their primary care providers survivorship care plans (SCPs).
SCPs are written documents that are often developed in
cancer programs and, ideally, include plans for follow-up
care, such as surveillance and preventive services, and
supporting information such as survivor’s diagnosis,
stage, and cancer treatments received. SCPs are
intended to facilitate communication and coordination
of care among survivors, cancer care providers, and
primary care providers [2]. SCP use is increasingly ad-
vised and required in guidelines issued by cancer care
quality improvement organizations (e.g., Commission
on Cancer) [2]. Despite increasingly pervasive guide-
lines for SCP use, a recent survey indicated that only
20% of United States oncologists reported always/almost
always providing SCPs [3]. Further, many providers de-
velop SCPs without delivering them to survivors or their
primary care providers [4].
Limited SCPs use in practice may relate, in part, to poor
quality of guidelines for SCP use. Guidelines are tools that
are intended to promote the use of recommended practices.
High-quality guidelines reflect the perspectives of relevant
stakeholder groups; provide clear guidance for implementa-
tion; are based on empirical evidence, explicit in their
methods of development, critically reviewed by experts,
and free from conflicts of interest; and are specific and
unambiguous [5]. Evidence suggests that providers’ in-
tentions to implement guidelines are stronger when
guidelines are clear and unambiguous [6,7]. Clear, un-
ambiguous guidelines for the use of SCPs might define
for whom and by whom SCPs should be developed,
when and where SCPs should be developed and deliv-
ered, to whom SCPs should be delivered, and what sur-
vivors and primary care providers should do with SCPs
once they receive them. Evidence of limited and incon-
sistent SCP use may suggest that cancer care providers
lack clear guidance regarding these questions [3,8].
Optimal responsibility and timing for developing and
delivering SCPs are unclear [3,9]; the utility of elec-
tronic SCPs has been debated [3,9-11]; and questions
remain regarding where SCPs are optimally delivered
(e.g., survivorship clinic, final treatment visit) [12,13].
The purpose of this study was to assess the quality of
guidelines for SCP use. Results may offer perspective on
why SCP use has been limited to date. If the quality of
guidelines for the use of SCPs is low, then developing
clearer, less ambiguous guidelines may represent a first
step toward promoting SCP use. If the quality of guide-
lines for the use of SCPs is high, then efforts may needto focus on multifaceted interventions to promote the
implementation of guidelines for SCP use in practice.
Methods
Literature search
For the purposes of this study, we used the IOM’s definition
of guidelines: “statements that include recommendations
intended to optimize patient care” ([14], p. 25). For in-
clusion in this study, we required guidelines to include
recommendations regarding the development, delivery,
and/or use of SCPs during follow-up care.
A broad range of literature was gathered to identify
guidelines for the use of SCPs. The following electronic
databases were searched for references to guidelines
related to SCPs published through April 15, 2014:
MEDLINE/PubMed (1946–2014), EMBASE (Excerpta
Medica Database) (1947–2014), and CINAHL (Cumu-
lative Index to Nursing and Allied Health Literature)
(1981–2014). In addition to the databases for indexed
scientific publications, we searched grey literature sources,
including websites of professional organizations and guide-
lines groups (see Additional file 1). The search used a
broad strategy that combined terms for ‘survivorship care
plans’ and ‘guidelines’.
Our initial search yielded 175 unduplicated records.
An additional 39 references were identified through
searches of guidelines groups’ and professional organi-
zations’ websites and publications. Additional file 1
identifies these websites and publications and depicts
our process of excluding records that did not contain
recommendations regarding the use of SCPs. Eighty-six
duplicates were removed, yielding 128 records. From
this, we eliminated 111 records that represented guidelines
for the use of clinical procedures, non-English publications,
childhood cancers, adult survivors of pediatric cancers,
models, programs, tools, editorials, dissertations, and
templates not accompanied by explicit SCP recommen-
dations. This yielded 17 unique records.
We sent the titles of the 17 records to six experts in the
field of cancer survivorship for review. These experts,
along with SB and DM, also experts in survivorship, were
asked to review the list to ensure accuracy and compre-
hensiveness. Experts suggested that the authors investigate
six additional resources that they believed might reveal
additional guidelines; three of these met the inclusion
criteria applied in previous rounds of the search,
resulting in 20 records that were included in our final
full-text review.
SB and SE independently conducted full-text review
of the 20 records, using two criteria for inclusion:
Records were required to constitute a guideline per
the IOM’s definition [14] and to include recommenda-
tions regarding the use of SCPs. Disagreements were
resolved through consensus and review by DM. Four
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guidelines to be evaluated.Data abstraction
Guidelines evaluated in the study included recommen-
dations regarding topics other than SCP use. Since the
purpose of this study was to evaluate the quality of guide-
lines for SCP use, we did not abstract data regarding
recommendations that did not relate to SCP use. To
extract data from guidelines related to SCP use, SB de-
veloped a data extraction form (see Additional file 2)
based on domains specified in the AGREE II instrument
(Appraisal of Guidelines for Research and Evaluation, 2nd
edition; www.agreetrust.org; domains described in detail in
the analysis section), a tool developed by an international
group of scientists to advance the quality of clinical practice
guidelines [15]. The form was reviewed and edited by
all authors.
SB and LD began by collaboratively extracting data
from one guideline. Then, we independently extracted
data from a second guideline and met to resolve discrep-
ancies. SB and LD then independently extracted data
from the remaining 14 guidelines. SE synthesized SB and
LD’s extracted data into a single form.Analysis
We assessed the overall quality of the 16 included guide-
lines using the AGREE II instrument. The validity and
reliability for assessment of practice guidelines using the
AGREE II have been established [15,16]. The instrument
includes 23 items that address six quality domains: (1)
scope and purpose, (2) stakeholder involvement, (3)
rigor of development, (4) clarity of presentation, (5) ap-
plicability, and (6) editorial independence. Two add-
itional assessment items (Overall Guideline Assessment)
pertain to an overall judgment of the guideline. Each
item is rated on a seven-point Likert scale, with 1
assigned for items with no clear discussion and 7 for ex-
ceptional quality of reporting. DC and LD read the entire
AGREE II user’s manual and then independently rated all
included guidelines.
Not all of the AGREE II items were applicable to
guidelines for SCP use. Items 11 (“The health benefits,
side effects, and risks have been considered in formulating
the recommendations.”) and 16 (“The different options for
management of the condition or health issue are clearly
presented.”) are limited in their applicability to SCPs;
evidence of benefits, risks, and alternatives is limited.
As such, these items were excluded from analysis. DC,
LD, and SB worked together to revise item 12 (“There
is an explicit link between the recommendations and
the supporting evidence.”); in light of limited empirical
evidence regarding SCPs, DC and LD interpreted item12 as “Evidence is described, and recommendations
follow from it”.
SB conducted the final scoring, according to the in-
strument protocol, by adding together DC and LD’s
respective ratings for items in each domain and stand-
ardizing the total score out of 100%.
The AGREE II manual does not provide guidance regard-
ing how to interpret scores. To promote consistency with
extant studies that have used the AGREE II instrument
[17,18], we adopted their method: Guidelines receiving a
standardized score of 50% or greater on all domains were
strongly recommended, guidelines receiving an overall as-
sessment of 50% or greater were recommended. and guide-
lines that neither received a standardized score of 50% or
greater on all domains nor received an overall assessment
of 50% or greater were not recommended.
Results
Guideline characteristics
Table 1 describes guideline characteristics. Sixteen guide-
lines were included in the review. Eleven were developed
in the United States; the remaining five guidelines were
developed in Canada [19], the Netherlands [20], the
United Kingdom, [21,22] and Australia [23]. Only three
guidelines focused specifically on SCP use [24-26]. In the
remaining 13, guidelines for SCP use were tangential;
11 [19-23,27-32] primarily focused on the care of can-
cer survivors, and two focused on standards for cancer
care programs [2,33].
AGREE II appraisal
Table 2 contains scores in each domain based on the
AGREE II appraisal. The quality of guidelines for SCP
use varied widely but was relatively low overall. We did
not strongly recommend any of the 16 guidelines, as
they did not receive a standardized score of 50% or
greater on all domains. We recommended five, as they
received an overall assessment of 50% or greater
[19,20,22,25,26]. We did not recommend the remaining
11 guidelines, as they neither received a standardized
score of 50% or greater on all domains nor received an
overall assessment of 50% or greater.
Domain 1: scope and purpose
Scope and purpose criteria relate to the objectives of the
guideline, health questions to be addressed, and target
population(s) [15]. The average guideline score for this
domain was low (42%). Descriptions of objectives were
vague (e.g., to provide the most appropriate follow-up
care to survivors), and only half of the guidelines de-
scribed the purpose of an SCP [20,24-30]. The National
Coalition for Cancer Survivorship (NCCS)/IOM/Lance
Armstrong Foundation/National Cancer Institute (NCI)
guideline, which performed best in this domain, described
Table 1 Guideline characteristics
Guideline Country of
origin
Focus Target audience Survivor
group
Alberta Health Services Canada Survivorship care Oncology providers; family physicians Breast
American Cancer Society United
States
Survivorship care None explicitly stated, but oncology
practitioners implied
None
specified
American Society of Clinical Oncology United
States
Survivorship care None explicitly stated, but oncology
practitioners implied
None
specified
Association of Community Cancer Centers United
States
Guidance for cancer
program development
Association of Community Cancer Centers
members; cancer care providers;
community cancer centers
None
specified
Commission on Cancer United
States
Standards for cancer
programs
None explicitly stated, but Commission on
Cancer members, cancer care providers,
and accredited cancer programs implied
None
specified
Comprehensive Cancer Center of the
Netherlands
Netherlands Survivorship care Cancer care professionals who discuss aftercare and
the cancer survivorship care plan with patients
treated with curative intent
Solid tumor
International Myeloma Foundation United
States
Survivorship care
plans
Members of the Nurse Leadership Board;
care providers for multiple myeloma
survivors; healthcare providers; nurses
Multiple
myeloma
Institute of Medicine United
States
Survivorship care Cancer care providers Breast,
prostate, and
colorectal
cancers;
Hodgkin’s
disease
LIVESTRONG United
States
Survivorship care Practitioners in any effective cancer
survivorship program
None
specified
National Breast and Ovarian Cancer
Centre
Australia Survivorship care Health care professionals Breast
National Comprehensive Cancer Network United
States
Survivorship care
plans
Health care professionals who care for survivors
of adult onset cancer in the post-treatment
period, including those in both oncology and
primary care practices
None
specified
National Coalition for Cancer Survivorship/
Institute of Medicine/ Lance Armstrong
Foundation/ National Cancer Institute
United
States
Survivorship care
plans
Clinical oncology providers; primary
care providers
None
specified
National Cancer Institute Community
Cancer Centers Program
United
States
Survivorship care
plans
Practitioners in National Cancer Institute
Community Cancer Centers Program
member programs
None
specified
National Collaborating Centre for Cancer United
Kingdom
Survivorship care Advanced practice nurses; nurses; pharmacists;
physician assistants; physicians
Breast
President’s Cancer Panel United
States
Survivorship care Health care providers None
specified
National Health Service United
Kingdom
Survivorship care Primary Care Trusts CEs, National Health Service
Trust CEs, Strategic Health Authorities CEs, Care
Trust CEs, Foundation Trust CEs, Medical Directors,
Directors of Nursing, Local Authority CEs, Directors
of Adult Social Services, Primary Care Trusts Chairs,
National Health Service Trust Board Chairs, Directors
of Human Resources, Directors of Finance, Allied
Health Professionals, General Practitioners,
Communications Leads, Directors of Children’s
Social Services (p 2); service users, carers, clinicians
and service commissioners. (p 5);
None
specified
CE chief executives.
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communicates what transpired during cancer treatment”,
functions “to promote a healthy lifestyle to preventrecurrence and reduce the risk of other comorbid condi-
tions”, and “gives patients an opportunity to take some
responsibility for their care and may help to ensure
Table 2 Guideline appraisal
Guideline Domain #1:
scope and
purpose
Domain #2: stakeholder
involvement
Domain #3: rigor
of development
Domain #4: clarity
of presentation
Domain #5:
applicability
Domain #6: editorial
independence
Overall
assessment
Recommendation
Alberta Health
Services
61% 35% 83% 63% 0% 75% 58% Recommended
American Cancer
Society
33% 6% 7% 46% 4% 8% 8% Not recommended
American Society of
Clinical Oncology
44% 36% 15% 75% 23% 46% 42% Not recommended
Association of
Community Cancer
Centers
19% 36% 2% 75% 4% 0% 17% Not recommended
Commission on
Cancer
19% 33% 12% 88% 19% 0% 33% Not recommended
Comprehensive
Cancer Center of the
Netherlands
69% 75% 56% 96% 38% 42% 67% Recommended
International Myeloma Foundation 56% 42% 17% 63% 21% 96% 42% Not recommended
Institute of Medicine 22% 42% 12% 92% 38% 38% 50% Not recommended
LIVESTRONG 33% 22% 10% 96% 31% 0% 33% Not recommended
National Breast and Ovarian
Cancer Centre
28% 58% 26% 46% 0% 63% 33% Not recommended
National Comprehensive Cancer
Network
72% 58% 26% 67% 31% 42% 50% Not recommended
National Coalition for Cancer
Survivorship/Institute of Medicine/
Lance Armstrong Foundation/
National Cancer Institute
92% 61% 18% 63% 52% 0% 58% Recommended
National Cancer Institute
Community Cancer Centers
Program
56% 42% 17% 88% 40% 29% 58% Recommended
National Collaborating Centre for
Cancer
19% 86% 69% 79% 40% 29% 58% Recommended
President’s Cancer Panel 11% 92% 7% 92% 15% 0% 25% Not recommended
National Health Service 31% 39% 5% 42% 0% 0% 25% Not recommended
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three guidelines described SCP-related health questions
specific to SCPs [21,25,30].The NCCS/IOM/Lance Arm-
strong Foundation/NCI guideline described a number of
SCP-specific health questions, including the following:
Who is responsible for creating the plan and discussing the
plan with patients? What are the respective roles of oncolo-
gists, primary care physicians, and nurses? What economic
strategies could encourage implementation of care plan-
ning? What barriers exist to creating the care plan? How
can they be overcome? [25]. Only three guidelines speci-
fied a target survivor group [2,27,31].
Domain 2: stakeholder involvement
Stakeholder involvement criteria relate to whether guide-
lines were developed with input from appropriate stake-
holders and reflect the views of intended users [15]. On
average, guidelines received a score of 48% for this domain.
Most guidelines did not adequately describe their guideline
development team. Four guidelines did not identify
members of the guideline development team [19,21,25,28].
Five guidelines identified the development team but did
not identify members’ professional groups [2,25,27,30,33].
Most guidelines did not describe including stakeholders
in guideline development, and those that did were
vague about stakeholders’ roles. Half of the guidelines
recommended particular providers to be primarily
responsible for developing and delivering SCPs, but rec-
ommendations were inconsistent across guidelines. Four
guidelines indicated that oncology providers have primary
responsibility for initiating them [2,25,31,32]. In some
cases, “oncology providers” referred to the primary on-
cologist [2,32]; in other cases, “oncology providers”
referred to the oncologist responsible for the last course of
treatment [32], oncology nurses [31,32], or some combin-
ation of physicians and nursing staff [25].
Domain 3: rigor of development
Rigor of development criteria relate to methods of gather-
ing and synthesizing evidence considered during guideline
development, processes of guideline development, and
methods for updating the guideline [15]. Only three guide-
lines described using systematic methods to search for
and review evidence [19,22,23]. Another three guidelines
discussed the current lack of definitive evidence on SCP
effectiveness [25,30,32]. Two guidelines [27,30] described
an explicit link between their recommendations and spe-
cific evidence, including studies on SCPs’ effectiveness,
cost efficiency, and time- and resource-intensiveness.
Most guidelines described guideline development pro-
cesses, but they did so with varying levels of detail. One
guideline, for example, detailed their recommendation
development process, describing an expert meeting, the
development of a list of essential elements of survivorshipcare, and consensus-building activities [29]. Others used
more general terms (e.g., “Priority topic areas … are deter-
mined in consultation with key stakeholders… A specific
multidisciplinary Working Group, including consumers, is
established for each topic identified and is involved in all
aspects of guideline development” [23]). Just half of the
guidelines discussed external expert review, and only two
[19,20] explicitly discussed procedures for updating their
document.
Domain 4: clarity of presentation
Clarity of presentation criteria include the following:
the recommendations are specific and unambiguous
and key recommendations are easily identifiable [15].
On average, guidelines received the highest scores in
this domain (73%). All 16 guidelines clearly endorsed
recommendations for SCP use; however, they varied in
degrees of specificity and lack of ambiguity. One guideline
was particularly specific and unambiguous in stating that,
in light of lack of evidence of SCPs’ effectiveness, SCP use
was recommended but not required [30]. Acknowledg-
ments of such uncertainty are consistent with AGREE II
guidance for evaluating Domain 4: “Evidence is not always
clear cut and there may be uncertainty about the best care
option(s); in this case, the uncertainty should be stated in
the guideline”. Most guidelines’ key recommendations
were generally readily identifiable (e.g., grouped together
in one section, summarized in a box, in boldface, or other-
wise emphasized).
Domain 5: applicability
Applicability criteria relate to facilitators and barriers to
implementing the guideline’s recommendations, strat-
egies for implementing the guideline’s recommendations,
and resource implications of implementation [15]. Of all
AGREE II domains, guidelines for SCP use received the
lowest scores in this domain (22%). Only six guidelines
discussed facilitators and barriers to SCP implementation
[20,25-27,29,32]. Half of the guidelines [2,20,25-27,29-31]
recommended a specific SCP template. All but two of the
guidelines [23,28] specified that SCPs should include both
a treatment summary and evidence-based follow-up care
plan. Most guidelines offered guidance about the timing of
SCP development and delivery. Of these, nine guidelines
[2,20-22,25,26,30-32] specified that SCPs should be deliv-
ered upon completion of active treatment and the transi-
tion to the post-treatment period; however, definitions of
this period varied from upon completion of primary can-
cer treatment and treatment for recurrence [31,32] to first
course of cancer treatment [2] to completion of active
treatment and subsequent transition points (e.g., further
disease; the move toward end-of-life care) [21]. Although
resource-intensiveness was identified as a potential barrier
to successful SCP implementation, resource implications
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one guideline offered auditing criteria for measuring
adherence to SCP recommendations (e.g., the percentage
of survivors in a practice with a SCP) [22].
Domain 6: editorial independence
Editorial independence criteria relate to ensuring lack of
bias in the development of the guideline [15]. The average
score for editorial independence was low (29%). Most
guidelines did not provide a statement regarding funding,
its influence on recommendations, or conflicts of interest.
Of guidelines that included a funding acknowledgment,
only two explicitly stated that their funding source did not
influence the recommendations [30,33].
Overall assessment
Overall guideline quality was low. Scores ranged from
8% [28] to 67% [20]. Only five guidelines [19-21,25,26]
received an overall score above 50%. Thus, we only
recommended these five guidelines and strongly rec-
ommended none.
Discussion
Overall, AGREE II domain scores suggest that the quality
of guidelines for SCP use is low. This finding is consistent
with that of other studies that have shown poor quality of
guidelines in cancer care [34]. Guidelines were generally
definitive in their recommendations to use SCPs, but these
recommendations were often not explicitly linked to evi-
dence. Further, guidelines for SCP use offered little clarity
regarding why, when, where, and how SCPs should be
used; who should use them; and for whom they should be
used. Only half of the guidelines explained the purpose of
SCPs [20,24-30]. Recommendations regarding when,
where, and by whom SCPs should be used varied across
guidelines. Most guidelines recommended that SCPs be
developed and delivered upon survivors’ transition to
follow-up care, but they differed in their definitions of the
transition period; only four guidelines indicated who
should develop and deliver SCPs [2,25,31,32]; and just six
specifically identified the cancer survivors to whom their
guideline applied [19,20,22-24,32].
The lack of clarity was underscored by the challenges
of abstracting guideline data. Two investigators ab-
stracted data, and a third reconciled abstractions. In
multiple instances, the independent abstractions led to
two reasonable but distinct interpretations of the guide-
lines. That two informed individuals could develop such
distinct interpretations of one guideline suggests that
busy clinicians may have difficulty culling relevant infor-
mation that is consistent with their peers’ practices. This
lack of guideline clarity may partly explain limited and
inconsistent SCP use in practice [4,35].As we suggested might be the case in the introduction,
the poor quality of guidelines for SCP use may contribute
to limited and inconsistent SCP use in practice [3,8]. Clear
and unambiguous guidelines for SCP use may promote
the effectiveness with which SCPs are implemented [6,7];
in effect, high-quality guidelines are an implementation
strategy [36]. In particular, guidelines that use behaviorally
specific terms may be the most effective way of increasing
implementation [6]. Guidelines for the use of SCPs may
be improved with precise and consistent definitions of
which templates are best to use; to whom the guideline
applies; to whom the guideline does not apply; and when,
where, and by whom SCPs may be most effectively devel-
oped and delivered. Clear specifications may facilitate
evaluation of adherence to guidelines. Future research
should assess the relationship between guideline quality
and the effectiveness of SCP implementation.
Many of the guidelines included in this study scored
highly in some, but not all, domains. Efforts to promote
SCP use may benefit from combining elements from mul-
tiple guidelines into a single clear, unambiguous resource.
SB, JW, LD, and colleagues are currently synthesizing in-
formation from the guidelines that scored highest in each
AGREE II domain in this study to create a “meta-guide-
line” for SCP use that practitioners may reference to fa-
cilitate their decision regarding adopting SCPs and,
should they adopt SCPs, to facilitate their implementa-
tion. By leveraging the work of existing guidelines, this
effort represents an efficient approach to facilitating
practitioners’ decisions around SCP adoption and
implementation.
Study limitations should be considered when interpreting
results. The search was conducted by a librarian with
expertise in systematic reviews; however, the search
may have excluded some guidelines. For example, we
excluded guidelines that were not published in English.
And although the AGREE II instrument is a useful tool
for evaluating guideline quality, it has limitations. In
particular, it does not offer guidance for interpreting
scores. Our criteria for strongly recommending, recom-
mending, or not recommending guidelines were intended
to promote consistency with extant studies using the
AGREE II instrument [17,18] and to clearly and unam-
biguously identify potentially useful guidelines for the use
of SCPs. In most cases, this resulted in overall assessment
scores that were commensurate with scores received on
individual domains. For this reason, the field of guideline
assessment may benefit from future AGREE II studies
using a similar method. Further, AGREE II only assesses
the quality of guidelines’ structure and content; it does not
assess the quality of guidelines’ recommendations. A case
in point, despite the variation in guidelines’ structural and
content quality that we found in this study, we found
almost no variation in guidelines’ recommendations in
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guidelines indicates room for improvement to facilitate
implementation of recommendations, neither our study
nor the AGREE II instrument offers insight into whether
the included guidelines’ recommendations are correct.
Another challenge of AGREE II relates to applying cri-
teria across several guidelines. Scores are intended to be
based on a guideline’s quality irrespective of other guide-
lines’ quality. However, as scoring proceeds, reviewers’
evaluations of guidelines becomes biased by familiarity
with previously scored guidelines. The quality of future
AGREE II evaluations may benefit from randomizing the
order in which each reviewer evaluates guidelines to
average out the effects of increased familiarity.Conclusions
Our findings indicate that the quality of guidelines for
SCP use is poor. Guideline quality may be improved
with more behaviorally specific information regarding
methods for effective SCP implementation. Organizations
that develop cancer-related guidelines may promote qual-
ity by incorporating AGREE II into their formal practice
guideline programs, as many other guideline-developing
organizations have successfully done [15].Additional filesAdditional file 1: Literature review flow diagram. Diagram of
literature sources and review process.
Additional file 2: Data extraction form. Form used to extract data
from guidelines related to SCP use.
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